

Amendments to the Claims:

Claims 1-30 (Canceled)

31. (Currently amended) A transgenic mouse whose genome comprises a ~~disruption in an endogenous null chemokine receptor 9A allele gene~~, wherein said null allele comprises exogenous DNA ~~where the disruption is homozygous, the transgenic mouse exhibits decreased agility, coordination or balance, relative to a wild-type mouse.~~
32. (Currently amended) The transgenic mouse of claim 31-23, wherein the transgenic mouse exhibits, relative to a wild-type mouse, ~~decreased agility, coordination or balance comprises decreased performance on an accelerating rotarod, when compared to a wild-type mouse.~~
33. (Previously presented) The transgenic mouse of claim 32, wherein the decreased performance is characterized by falling from an accelerating rotarod at lower speeds relative to a wild-type mouse.
34. (Currently amended) A cell obtained from the transgenic mouse of claim 31-23.

Claims 35-37 (Canceled)

38. (Currently amended) A method of producing ~~the~~ a transgenic mouse of claim 31 ~~comprising a disruption in an endogenous chemokine receptor 9A gene~~, the method comprising:
- a) providing a mouse embryonic stem cell ~~comprising a disruption in an endogenous whose genome comprises a null chemokine receptor 9A allele gene~~;
 - b) introducing the mouse embryonic stem cell into a blastocyst;
 - c) implanting the resulting blastocyst into a pseudopregnant mouse, wherein said pseudopregnant mouse gives birth to a chimeric mouse; and
 - d) breeding the chimeric mouse to produce the transgenic mouse, ~~comprising a disruption in the endogenous chemokine receptor 9A gene~~;
~~wherein where the disruption is homozygous, the transgenic mouse exhibits decreased agility, coordination or balance, relative to a wild-type mouse~~
39. (Canceled)
40. (New) The transgenic mouse of claim 31, wherein the transgenic mouse is homozygous for said null allele.
41. (New) The transgenic mouse of claim 31, wherein the transgenic mouse is heterozygous for said null allele.

42. (New) The transgenic mouse of claim 31, wherein the exogenous DNA comprises a gene encoding a selectable marker.
43. (New) The transgenic mouse of claim 42 wherein said gene comprises a neomycin resistant gene.